Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.23
GSK's Cash-to-Debt is ranked lower than
85% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. GSK: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
GSK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.42 Max: 7.44
Current: 0.23
0.02
7.44
Debt-to-Equity -253.00
GSK's Debt-to-Equity is ranked lower than
99.99% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. GSK: -253.00 )
Ranked among companies with meaningful Debt-to-Equity only.
GSK' s Debt-to-Equity Range Over the Past 10 Years
Min: -253  Med: 1.16 Max: 140.3
Current: -253
-253
140.3
Debt-to-EBITDA 2.90
GSK's Debt-to-EBITDA is ranked lower than
59% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GSK: 2.90 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GSK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.29  Med: 2.08 Max: 4.26
Current: 2.9
1.29
4.26
Interest Coverage 8.74
GSK's Interest Coverage is ranked lower than
80% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. GSK: 8.74 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 3.66  Med: 8.29 Max: 10.76
Current: 8.74
3.66
10.76
Piotroski F-Score: 4
Altman Z-Score: 1.24
Beneish M-Score: -3.09
WACC vs ROIC
6.80%
18.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 20.02
GSK's Operating Margin % is ranked higher than
66% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. GSK: 20.02 )
Ranked among companies with meaningful Operating Margin % only.
GSK' s Operating Margin % Range Over the Past 10 Years
Min: 10.99  Med: 21.91 Max: 29.7
Current: 20.02
10.99
29.7
Net Margin % 3.45
GSK's Net Margin % is ranked lower than
53% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. GSK: 3.45 )
Ranked among companies with meaningful Net Margin % only.
GSK' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 17.96 Max: 35.2
Current: 3.45
3.27
35.2
ROE % 140.55
GSK's ROE % is ranked higher than
100% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. GSK: 140.55 )
Ranked among companies with meaningful ROE % only.
GSK' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 61.62 Max: 290.15
Current: 140.55
17.3
290.15
ROA % 1.79
GSK's ROA % is ranked lower than
53% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. GSK: 1.79 )
Ranked among companies with meaningful ROA % only.
GSK' s ROA % Range Over the Past 10 Years
Min: 1.62  Med: 11.7 Max: 17.9
Current: 1.79
1.62
17.9
ROC (Joel Greenblatt) % 35.15
GSK's ROC (Joel Greenblatt) % is ranked higher than
83% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. GSK: 35.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GSK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.79  Med: 77.34 Max: 120.14
Current: 35.15
25.79
120.14
3-Year Revenue Growth Rate 8.90
GSK's 3-Year Revenue Growth Rate is ranked higher than
63% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GSK: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GSK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.6  Med: 5.5 Max: 18
Current: 8.9
-7.6
18
3-Year EBITDA Growth Rate 5.70
GSK's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. GSK: 5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GSK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.4  Med: 7.1 Max: 96.3
Current: 5.7
-41.4
96.3
3-Year EPS without NRI Growth Rate -18.20
GSK's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. GSK: -18.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GSK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 5 Max: 51.3
Current: -18.2
-44.8
51.3
GuruFocus has detected 5 Warning Signs with GlaxoSmithKline PLC GSK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GSK's 30-Y Financials

Financials (Next Earnings Date: 2018-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

GSK Guru Trades in Q2 2017

Steven Cohen 100,000 sh (New)
Jim Simons 9,338,000 sh (+112.13%)
Sarah Ketterer 425,047 sh (+34.72%)
Pioneer Investments 623,997 sh (+15.23%)
Ken Fisher 12,534,385 sh (+4.72%)
Joel Greenblatt 26,495 sh (+4.34%)
HOTCHKIS & WILEY 7,847,327 sh (+4.29%)
Kahn Brothers 1,055,085 sh (+0.39%)
Diamond Hill Capital 190,052 sh (unchged)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
John Rogers 1,646,146 sh (unchged)
Murray Stahl 24,073 sh (unchged)
Charles Brandes 3,361,346 sh (-0.07%)
Tweedy Browne 109,584 sh (-0.90%)
Jeff Auxier 86,909 sh (-1.40%)
PRIMECAP Management 1,075,535 sh (-1.69%)
NWQ Managers 2,494,769 sh (-2.87%)
Dodge & Cox 29,687 sh (-7.77%)
John Paulson 289,500 sh (-30.26%)
Jeremy Grantham 304,800 sh (-50.07%)
» More
Q3 2017

GSK Guru Trades in Q3 2017

T Rowe Price Equity Income Fund 1,675,000 sh (New)
Dodge & Cox 14,858,137 sh (+49949.30%)
Steven Cohen 604,419 sh (+504.42%)
Jeremy Grantham 827,900 sh (+171.62%)
Sarah Ketterer 550,910 sh (+29.61%)
NWQ Managers 2,728,458 sh (+9.37%)
Murray Stahl 25,975 sh (+7.90%)
HOTCHKIS & WILEY 8,416,927 sh (+7.26%)
Joel Greenblatt 27,193 sh (+2.63%)
John Rogers 1,684,870 sh (+2.35%)
Ken Fisher 12,828,251 sh (+2.34%)
Diamond Hill Capital 193,983 sh (+2.07%)
Jim Simons 9,437,700 sh (+1.07%)
First Eagle Investment 1 sh (unchged)
PRIMECAP Management 1,075,535 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
John Paulson Sold Out
Tweedy Browne 109,194 sh (-0.36%)
Jeff Auxier 86,372 sh (-0.62%)
Pioneer Investments 619,175 sh (-0.77%)
Kahn Brothers 1,021,135 sh (-3.22%)
Charles Brandes 2,132,764 sh (-36.55%)
» More
Q4 2017

GSK Guru Trades in Q4 2017

Dodge & Cox 44,083,293 sh (+196.69%)
Tweedy Browne 197,274 sh (+80.66%)
T Rowe Price Equity Income Fund 2,490,000 sh (+48.66%)
Jeremy Grantham 1,064,700 sh (+28.60%)
Sarah Ketterer 630,163 sh (+14.39%)
Kahn Brothers 1,139,163 sh (+11.56%)
Charles Brandes 2,262,946 sh (+6.10%)
John Rogers 1,779,641 sh (+5.62%)
Joel Greenblatt 27,917 sh (+2.66%)
Jim Simons 9,668,300 sh (+2.44%)
Diamond Hill Capital 197,723 sh (+1.93%)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
Steven Cohen Sold Out
HOTCHKIS & WILEY 8,410,527 sh (-0.08%)
PRIMECAP Management 1,072,535 sh (-0.28%)
Ken Fisher 12,779,721 sh (-0.38%)
Jeff Auxier 86,022 sh (-0.41%)
NWQ Managers 2,642,926 sh (-3.13%)
Murray Stahl 24,173 sh (-6.94%)
Pioneer Investments 488,321 sh (-21.13%)
» More
Q1 2018

GSK Guru Trades in Q1 2018

Sarah Ketterer 920,777 sh (+46.12%)
Jeremy Grantham 1,510,700 sh (+41.89%)
Dodge & Cox 48,551,967 sh (+10.14%)
Kahn Brothers 1,230,642 sh (+8.03%)
Charles Brandes 2,389,464 sh (+5.59%)
Ken Fisher 13,428,344 sh (+5.08%)
NWQ Managers 2,743,443 sh (+3.80%)
HOTCHKIS & WILEY 8,544,527 sh (+1.59%)
Murray Stahl 24,423 sh (+1.03%)
Joel Greenblatt 27,916 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
First Eagle Investment Sold Out
T Rowe Price Equity Income Fund 2,480,000 sh (-0.40%)
John Rogers 1,771,550 sh (-0.45%)
Pioneer Investments 485,781 sh (-0.52%)
Tweedy Browne 194,093 sh (-1.61%)
PRIMECAP Management 1,047,435 sh (-2.34%)
Jeff Auxier 83,572 sh (-2.85%)
Diamond Hill Capital 189,130 sh (-4.35%)
Jim Simons 8,112,800 sh (-16.09%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2018-03-31 Add 10.14%0.14%$35.47 - $39.38 $ 41.4411%48,551,967
Ken Fisher 2018-03-31 Add 5.08%0.03%$35.47 - $39.38 $ 41.4411%13,428,344
HOTCHKIS & WILEY 2018-03-31 Add 1.59%0.02%$35.47 - $39.38 $ 41.4411%8,544,527
NWQ Managers 2018-03-31 Add 3.80%0.06%$35.47 - $39.38 $ 41.4411%2,743,443
T Rowe Price Equity Income Fund 2018-03-31 Reduce -0.40%$35.47 - $39.38 $ 41.4411%2,480,000
Charles Brandes 2018-03-31 Add 5.59%0.11%$35.47 - $39.38 $ 41.4411%2,389,464
John Rogers 2018-03-31 Reduce -0.45%$35.47 - $39.38 $ 41.4411%1,771,550
Kahn Brothers 2018-03-31 Add 8.03%0.57%$35.47 - $39.38 $ 41.4411%1,230,642
Tweedy Browne 2018-03-31 Reduce -1.61%$35.47 - $39.38 $ 41.4411%194,093
First Eagle Investment 2018-03-31 Sold Out $35.47 - $39.38 $ 41.4411%0
Dodge & Cox 2017-12-31 Add 196.69%0.8%$34.66 - $41.1 $ 41.4412%44,083,293
Ken Fisher 2017-12-31 Reduce -0.38%$34.66 - $41.1 $ 41.4412%12,779,721
HOTCHKIS & WILEY 2017-12-31 Reduce -0.08%$34.66 - $41.1 $ 41.4412%8,410,527
NWQ Managers 2017-12-31 Reduce -3.13%0.05%$34.66 - $41.1 $ 41.4412%2,642,926
T Rowe Price Equity Income Fund 2017-12-31 Add 48.66%0.13%$34.66 - $41.1 $ 41.4412%2,490,000
Charles Brandes 2017-12-31 Add 6.10%0.09%$34.66 - $41.1 $ 41.4412%2,262,946
John Rogers 2017-12-31 Add 5.62%0.04%$34.66 - $41.1 $ 41.4412%1,779,641
Kahn Brothers 2017-12-31 Add 11.56%0.66%$34.66 - $41.1 $ 41.4412%1,139,163
Tweedy Browne 2017-12-31 Add 80.66%0.08%$34.66 - $41.1 $ 41.4412%197,274
Joel Greenblatt 2017-12-31 Add 2.66%$34.66 - $41.1 $ 41.4412%27,917
Dodge & Cox 2017-09-30 Add 49949.30%0.49%$38.68 - $42.77 $ 41.442%14,858,137
Ken Fisher 2017-09-30 Add 2.34%0.02%$38.68 - $42.77 $ 41.442%12,828,251
HOTCHKIS & WILEY 2017-09-30 Add 7.26%0.09%$38.68 - $42.77 $ 41.442%8,416,927
NWQ Managers 2017-09-30 Add 9.37%0.14%$38.68 - $42.77 $ 41.442%2,728,458
Charles Brandes 2017-09-30 Reduce -36.55%0.84%$38.68 - $42.77 $ 41.442%2,132,764
John Rogers 2017-09-30 Add 2.35%0.02%$38.68 - $42.77 $ 41.442%1,684,870
T Rowe Price Equity Income Fund 2017-09-30 New Buy0.33%$38.68 - $42.77 $ 41.442%1,675,000
Kahn Brothers 2017-09-30 Reduce -3.22%0.22%$38.68 - $42.77 $ 41.442%1,021,135
Tweedy Browne 2017-09-30 Reduce -0.36%$38.68 - $42.77 $ 41.442%109,194
Joel Greenblatt 2017-09-30 Add 2.63%$38.68 - $42.77 $ 41.442%27,193
John Paulson 2017-09-30 Sold Out 0.17%$38.68 - $42.77 $ 41.442%0
Ken Fisher 2017-06-30 Add 4.72%0.04%$40.68 - $44.37 $ 41.44-3%12,534,385
HOTCHKIS & WILEY 2017-06-30 Add 4.29%0.06%$40.68 - $44.37 $ 41.44-3%7,847,327
Charles Brandes 2017-06-30 Reduce -0.07%$40.68 - $44.37 $ 41.44-3%3,361,346
NWQ Managers 2017-06-30 Reduce -2.87%0.04%$40.68 - $44.37 $ 41.44-3%2,494,769
Kahn Brothers 2017-06-30 Add 0.39%0.03%$40.68 - $44.37 $ 41.44-3%1,055,085
John Paulson 2017-06-30 Reduce -30.26%0.07%$40.68 - $44.37 $ 41.44-3%289,500
Tweedy Browne 2017-06-30 Reduce -0.90%$40.68 - $44.37 $ 41.44-3%109,584
Dodge & Cox 2017-06-30 Reduce -7.77%$40.68 - $44.37 $ 41.44-3%29,687
Joel Greenblatt 2017-06-30 Add 4.34%$40.68 - $44.37 $ 41.44-3%26,495
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XPAR:SAN, XTER:BAYN, NYSE:LLY, LSE:AZN, NYSE:BMY, NYSE:ABBV, NYSE:MRK, TSE:4503, TSE:4519, TSE:4578, TSE:4568, XSWX:NOVN, HKSE:01093, TSE:4151, TSE:4528, XSWX:ROG, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Guru Investment Theses on GlaxoSmithKline PLC

Dodge & Cox Comments on GlaxoSmithKline - Feb 13, 2018

The Fund recently re-established a position in GlaxoSmithKline (NYSE:GSK), after selling it in 2015. Based in the United Kingdom, the company has leading therapeutic franchises in respiratory care and HIV. In addition to its traditional pharmaceuticals business, the company is diversified through strong and growing businesses in vaccines and over-the-counter consumer health.



In 2015, we sold GlaxoSmithKline based on market headwinds and a higher valuation. The company’s pharmaceuticals business was suffering from pricing pressure on a key respiratory drug, Advair, and the pipeline of new drug launches was weak. The valuation, at 20 times forward earnings, was relatively expensive and did not sufficiently compensate for the risks. Some of those risks, including continued weakness in Advair sales, materialized, and the valuation declined after we sold the position.



In the second half of 2017, however, we built a position in GlaxoSmithKline again based on a more favorable fundamental long-term outlook and a lower valuation (12 times forward earnings). In the respiratory care division, declines in Advair sales should be offset by new drugs, aided by a new inhaler. The HIV segment is growing at healthy rates due to increased adoption of Dolutegravir, a drug that blocks an enzyme needed for HIV to replicate. Combined with continued growth in vaccines and consumer health, the company should achieve modest earnings growth. Meanwhile, the management team has also been revamped. The new CEO is focusing on renewing the pharmaceutical pipeline and has brought in a well-regarded head of R&D to lead that effort. Improvements in the drug pipeline will take time to manifest, but in the meantime, the company continues to generate stable cash flow and has an attractive 6% dividend yield. On December 31, GlaxoSmithKline was a 1.4% position in the Fund.



From Dodge & Cox's fourth quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Ariel Funds Comments on GlaxoSmithKline plc - Sep 28, 2016

In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair.

From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
New Research: Key Drivers of Growth for BP p.l.c, Petroleo Brasileiro S.A.- Petrobras, Transocean, GlaxoSmithKline plc, Noble, and Grupo Televisa S.A. — Factors of Influence, Major Initiatives and Sustained Production
Bayer Closes Merger With Buffett’s Monsanto Combined company expects to improve productivity and sustainability of agricultural companies
Bayer AG (XTER:BAYN)(BAYRY) announced on Thursday that it closed its merger with Monsanto Co. (NYSE:MON), a company Warren Buffett (Trades, Portfolio) invested in 7.26 million shares during the first quarter. Read more...
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
Kahn Brothers Boosts 3 Positions in 1st Quarter Investment firm discloses quarterly portfolio
Kahn Brothers (Trades, Portfolio), founded by legendary investor Irving Kahn, follows a Benjamin Graham-style investing approach. On Tuesday, the firm disclosed it increased its position in three companies during the first quarter: Assured Guaranty Ltd. (NYSE:AGO), New York Community Bancorp Inc. (NYSE:NYCB) and GlaxoSmithKline PLC (NYSE:GSK). Read more...
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
NeuroMetrix Reports Q1 2018 Financial Results

Ratios

vs
industry
vs
history
PE Ratio 73.51
GSK's PE Ratio is ranked lower than
71% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. GSK: 73.51 )
Ranked among companies with meaningful PE Ratio only.
GSK' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 15.08 Max: 99999999.99
Current: 73.51
6.35
99999999.99
Forward PE Ratio 14.47
GSK's Forward PE Ratio is ranked higher than
81% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. GSK: 14.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 73.51
GSK's PE Ratio without NRI is ranked lower than
70% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. GSK: 73.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
GSK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.35  Med: 15.08 Max: 99999999.99
Current: 73.51
6.35
99999999.99
Price-to-Owner-Earnings 19.31
GSK's Price-to-Owner-Earnings is ranked higher than
59% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.72 vs. GSK: 19.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GSK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.24  Med: 14.67 Max: 105.31
Current: 19.31
5.24
105.31
PS Ratio 2.55
GSK's PS Ratio is ranked higher than
61% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. GSK: 2.55 )
Ranked among companies with meaningful PS Ratio only.
GSK' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.7 Max: 3.46
Current: 2.55
1.94
3.46
Price-to-Free-Cash-Flow 16.94
GSK's Price-to-Free-Cash-Flow is ranked higher than
76% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. GSK: 16.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GSK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 15.72 Max: 136.91
Current: 16.94
8.24
136.91
Price-to-Operating-Cash-Flow 11.47
GSK's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. GSK: 11.47 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GSK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 11.45 Max: 27.46
Current: 11.47
6.62
27.46
EV-to-EBIT 24.80
GSK's EV-to-EBIT is ranked higher than
51% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. GSK: 24.80 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 12.1 Max: 72.6
Current: 24.8
6.3
72.6
EV-to-EBITDA 15.56
GSK's EV-to-EBITDA is ranked higher than
70% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. GSK: 15.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 10 Max: 35.2
Current: 15.56
5.6
35.2
EV-to-Revenue 3.13
GSK's EV-to-Revenue is ranked higher than
57% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. GSK: 3.13 )
Ranked among companies with meaningful EV-to-Revenue only.
GSK' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.1 Max: 4
Current: 3.13
2.3
4
Shiller PE Ratio 17.61
GSK's Shiller PE Ratio is ranked higher than
88% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. GSK: 17.61 )
Ranked among companies with meaningful Shiller PE Ratio only.
GSK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.71  Med: 15.15 Max: 18.82
Current: 17.61
11.71
18.82
Current Ratio 0.61
GSK's Current Ratio is ranked lower than
97% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. GSK: 0.61 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.26 Max: 2.64
Current: 0.61
0.57
2.64
Quick Ratio 0.40
GSK's Quick Ratio is ranked lower than
97% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. GSK: 0.40 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.97 Max: 2.24
Current: 0.4
0.37
2.24
Days Inventory 200.26
GSK's Days Inventory is ranked lower than
82% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. GSK: 200.26 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 186.27 Max: 202.64
Current: 200.26
167.28
202.64
Days Sales Outstanding 74.23
GSK's Days Sales Outstanding is ranked lower than
51% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. GSK: 74.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 58.77 Max: 93.9
Current: 74.23
54.62
93.9
Days Payable 753.14
GSK's Days Payable is ranked lower than
99.99% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. GSK: 753.14 )
Ranked among companies with meaningful Days Payable only.
GSK' s Days Payable Range Over the Past 10 Years
Min: 98.94  Med: 126.57 Max: 753.14
Current: 753.14
98.94
753.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.23
GSK's Dividend Yield % is ranked higher than
97% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. GSK: 5.23 )
Ranked among companies with meaningful Dividend Yield % only.
GSK' s Dividend Yield % Range Over the Past 10 Years
Min: 3.7  Med: 4.99 Max: 6.24
Current: 5.23
3.7
6.24
Dividend Payout Ratio 3.85
GSK's Dividend Payout Ratio is ranked lower than
62% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. GSK: 3.85 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GSK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 3.85
0.46
4.3
Forward Dividend Yield % 5.23
GSK's Forward Dividend Yield % is ranked higher than
97% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. GSK: 5.23 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.68
GSK's 5-Year Yield-on-Cost % is ranked higher than
93% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. GSK: 5.68 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GSK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.03  Med: 5.43 Max: 6.79
Current: 5.68
4.03
6.79
3-Year Average Share Buyback Ratio -0.60
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. GSK: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.5  Med: -0.5 Max: 3.9
Current: -0.6
-26.5
3.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.29
GSK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. GSK: 2.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GSK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.08  Med: 2.42 Max: 624.5
Current: 2.29
1.08
624.5
Price-to-Median-PS-Value 0.94
GSK's Price-to-Median-PS-Value is ranked higher than
73% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. GSK: 0.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GSK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.23 Max: 3.51
Current: 0.94
0.64
3.51
Earnings Yield (Greenblatt) % 4.04
GSK's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. GSK: 4.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GSK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 8.25 Max: 15.8
Current: 4.04
1.4
15.8
Forward Rate of Return (Yacktman) % -7.63
GSK's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. GSK: -7.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GSK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.1  Med: 7.85 Max: 28.1
Current: -7.63
-9.1
28.1

More Statistics

Revenue (TTM) (Mil) $40,156.47
EPS (TTM) $ 0.57
Beta0.70
Volatility16.90%
52-Week Range $34.52 - 44.45
Shares Outstanding (Mil)2,479.76 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 39,805 40,441 41,502
EBIT (Mil $) 10,414 10,749 12,356
EBITDA (Mil $) 12,576 12,936 14,651
EPS ($) 1.95 2.29 2.62
EPS without NRI ($) 1.95 2.29 2.62
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.87%
Dividends per Share ($) 2.14 2.14 2.14

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}